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ABSTRACT Chronic, biofilm-like infections by the opportunistic pathogen Pseudomonas aeruginosa are a major cause of mortal-
ity in cystic fibrosis (CF) patients. While much is known about P. aeruginosa from laboratory studies, far less is understood
about what it experiences in vivo. Iron is an important environmental parameter thought to play a central role in the develop-
ment and maintenance of P. aeruginosa infections, for both anabolic and signaling purposes. Previous studies have focused on
ferric iron [Fe(III)] as a target for antimicrobial therapies; however, here we show that ferrous iron [Fe(II)] is abundant in the CF
lung (~39Mon average for severely sick patients) and significantly correlates with disease severity (0.56, P 0.004),
whereas ferric iron does not (0.28, P 0.179). Expression of the P. aeruginosa genes bqsRS, whose transcription is upregu-
lated in response to Fe(II), was high in the majority of patients tested, suggesting that increased Fe(II) is bioavailable to the infec-
tious bacterial population. Because limiting Fe(III) acquisition inhibits biofilm formation by P. aeruginosa in various oxic in
vitro systems, we also tested whether interfering with Fe(II) acquisition would improve biofilm control under anoxic conditions;
concurrent sequestration of both iron oxidation states resulted in a 58% reduction in biofilm accumulation and 28% increase in
biofilm dissolution, a significant improvement over Fe(III) chelation treatment alone. This study demonstrates that the chemis-
try of infected host environments coevolves with the microbial community as infections progress, which should be considered in
the design of effective treatment strategies at different stages of disease.
IMPORTANCE Iron is an important environmental parameter that helps pathogens thrive in sites of infection, including those of
cystic fibrosis (CF) patients. Ferric iron chelation therapy has been proposed as a novel therapeutic strategy for CF lung infec-
tions, yet until now, the iron oxidation state has not beenmeasured in the host. In studying mucus from the infected lungs of
multiple CF patients from Europe and the United States, we found that ferric and ferrous iron change in concentration and rela-
tive proportion as infections progress; over time, ferrous iron comes to dominate the iron pool. This information is relevant to
the design of novel CF therapeutics and, more broadly, to developing accurate models of chronic CF infections.
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Both culture-dependent and molecular identification methodssuggest that Pseudomonas aeruginosa is a dominant bacterial
pathogen of patients with cystic fibrosis (CF) (1). As P. aeruginosa
adapts to the host environment, it adopts a biofilm-like lifestyle
associated with enhanced antibiotic resistance, persistent infec-
tions, and poor pulmonary prognosis (2). Numerous studies have
documented how P. aeruginosa responds to specific environmen-
tal cues, including hypoxia, that are thought to be relevant for
biofilm formation and chronic colonization in vivo (3, 4); how-
ever, only a few studies have directly measured chemical parame-
ters within the host, and usually only at a single time point (5, 6).
This knowledge gap is an important one to fill because pathogens
are known to coevolve with host environmental chemistry with
respect to their metabolic programs and growth phenotypes, in-
cluding biofilm formation (2, 7). Toward this end, we sought to
characterize the oxidation state of iron within CF sputum and the
biological response of P. aeruginosa at different disease states for a
cross section of CF patients.
The competition for iron between pathogens and the human
host has been extensively studied due to its critical importance in
pathogenesis (8, 9). In particular, iron has been identified as an
important parameter that plays a central role in the development
and maintenance of P. aeruginosa biofilm infections within the
lung (10–12). On this basis, iron uptake and acquisition pathways
have been identified as potential antimicrobial targets (10–15).
While microbial ferrous iron [Fe(II)] acquisition pathways are
known (16), therapeutic strategies designed to iron-limit patho-
gens have focused on blocking ferric iron [Fe(III)] acquisition
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because it is commonly assumed to be the dominant physiologi-
cally relevant form. For example, Fe(III) chelation by the host
immune protein lactoferrin and its analog, conalbumin, has been
shown to dramatically reduce biofilm formation under oxic con-
ditions (11–13). EDTA and FDA-approved iron chelation com-
pounds are similarly effective at mitigating biofilm growth while
concomitantly increasing the efficacy of conventional antibiotics
(13, 15). In addition, the transition metal gallium (also FDA ap-
proved) has been shown to disrupt biofilm formation by virtue of
its chemical similarity to iron, disrupting Fe(III) uptake and in-
terfering with Fe signaling (17, 18).
Despite the success of these Fe sequestration strategies in lab-
oratory models, for many of them to be effective in vivo, iron
would need to exist in the ferric form. However, in late-stage dis-
ease, oxygen tension is reduced in the lung (5) and neutrophil-
mediated superoxides are generated that can reduce organically
complexed Fe(III) to Fe(II) (19, 20). In addition, dense, biofilm-
like microcolonies form within sputum that can create hypoxic
microenvironments that can maintain iron in its reduced state
(21). Furthermore, P. aeruginosa produces a variety of redox-
active metabolites in CF sputum (e.g., phenazines) (22) that can
reduce Fe(III) to Fe(II), evenwhen iron is bound to host chelation
proteins (23).While theCF lung environment is likely to be chem-
ically heterogeneous, with oxic, hypoxic, and anoxic zones, the
potential for locally anoxic and reducing conditions caused us to
suspect that Fe(II) might be abundant in the airways. This report
describes how we tested this hypothesis and explored its conse-
quences for the development of iron-specific therapeutic strate-
gies.
RESULTS
Total and ferrous iron concentrations increase within the lung
environment as infections progress. Although the total concen-
tration of iron has been measured in the airways (24, 25) and is
known to accumulate in the lavage and explanted lungs of CF
patients (26), its oxidation state has not been defined. We there-
fore set out to measure Fe(II) abundance in CF sputum at differ-
ent stages of disease progression. Accurately measuring the iron
oxidation state is complicated by the rapid oxidation of Fe(II) to
Fe(III) once expectorated sputum is exposed to ambient oxygen.
With this in mind, we designed a sputum collection and process-
ing approach to better preserve and measure iron in its in vivo
oxidation state. Twenty-four pediatric patients from across the
spectrum of disease severity provided 115 sputum samples that
were rapidly flash frozen upon expectoration. Samples were then
moved to an anaerobic chamber to impede oxidation and me-
chanically homogenized by syringe, and ratios of free Fe(II)/
Fe(III) concentrations were then determined using the ferrozine
assay. As controls, total iron levels were also assayed using induc-
tively coupled plasma mass spectrometry (ICP-MS) and un-
treated samples stored under argon were compared to flash-
frozen samples to test whether the iron oxidation state was
faithfully preserved during cryostorage (see Fig. S1 in the supple-
mental material).
Due to the temporal variability of sputum iron concentrations
and differences in the number of samples that we were able to
collect for a given patient (see Table S1 in the supplemental ma-
terial), we grouped data over the entire period of the study and
treated each patient’s iron measurements as an average, rather
than as independent observations, in order to test for correlations
with patient disease state (Table 1). Using this data set, clustered
by patient (n 24), Spearman rank analysis revealed a significant
negative correlation (  0.48, P  0.018) between total iron
and declining lung function (measured by forced expiratory vol-
ume [FEV1%]) (Fig. 1A; Table 2). Elevated iron levels (62 
20 M for severely infected patients) (Table 1) were consistent
with previous studies that quantified total iron levels and iron-
related proteins in the CF airways (24–26). Consistent with our
hypothesis, a considerable amount of this iron was found in its
ferrous form, as sputum from severely infected patients had 39
22 M Fe(II). Here, we found a highly significant negative corre-
lation between absolute Fe(II) concentrations and disease status
(  0.56, P  0.004) (Fig. 1B), though a similar relationship
was not found for Fe(III) (0.28, P 0.179) (Fig. 1C). The
percentage of the total iron pool that was present as Fe(II) was also
higher (though not significantly:   0.36, P  0.083) in pa-
tients with advanced disease states; in patients with severe lung
obstruction (FEV1%,40), Fe(II) constituted 56% 15% of the
total iron pool (Fig. 1D). These data reveal that the chemical en-
vironment of the lung is dynamic and evolves with respect to its
iron redox chemistry as CF disease progresses.
Increased Fe(II) correlates with elevated phenazine concen-
trations.The alteration of total iron concentrations and the rise in
Fe(II) over time likely result from multiple inputs by both host
and pathogen (24, 26). For example, iron levels are known to
increase due to inflammation (27); loss of intracellular iron by
F508 epithelial cells (28); altered production of the iron-related
proteins heme, ferritin, and transferrin (26); and their proteolysis
(29). In addition, redox-active phenazine metabolites produced
by P. aeruginosa are abundant in CF sputum (22), some of which
can readily reduce Fe(III) to Fe(II) (30). Iron reduction by
phenazines has been demonstrated to circumvent iron chelation
in vitro, promoting the formation of biofilms (31). Based on our
recent demonstration of a strong correlation between sputum
phenazine levels and pulmonary decline (22), we used high-
pressure liquid chromatography (HPLC) to assess whether ele-
vated levels of two phenazines, pyocyanin (PYO) and phenazine-
1-carboxylic acid (PCA), also correlated with high Fe(II)
concentrations. Consistent with our previous findings from an
independent adult patient cohort, themajority of sputum samples
tested had detectable phenazine concentrations (76 of 97 samples
tested contained 10 M total phenazine; see Table S1 in the
supplemental material). In sputum samples with low concentra-
tions of phenazines, the percentage of the total iron pool that was
Fe(II) ranged anywhere from0 to 100%, revealing that phenazines
are not required for the presence of ferrous iron (Fig. 2A). Yet,
phenazines may facilitate Fe(III) reduction in vivo, as evidenced
by the generally high percentage of Fe(II) once phenazine levels
TABLE 1 Summary of average Fe concentrations grouped by disease
severitya
Disease severity FEV1% n Total Fe (M) Fe(II) (M) Fe(II) %
Normal to mild 70 7 18 14 7 8 41 28
Moderate 40–69 12 48 38 28 27 52 10
Severe 40 5 62 20 39 22 56 15
a Reported values are mean concentrations 1 standard deviation of iron detected in
sputum samples collected over the study period. Values are conservative estimates
based on ferrozine and ICP-MS measurements (see Fig. S1 in the supplemental
material).
Hunter et al.
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rise above~50Min expectorated sputum.Treating each sputum
sample independently, we found a strong trend between PCA
abundance and Fe(II)% ( 0.185,P 0.069), yet no correlation
between PYO abundance and Fe(II) % (  0.042, P  0.67)
(Fig. 2B and C). This may reflect that PCA can reduce Fe(III)
much faster than can PYO under anoxic conditions (30). It re-
mains to be determined whether the PCA/Fe(II) % trend would
pass our test of statistical significance (P  0.05) with additional
sampling. We treated samples independently in this analysis in
order to compare phenazine concentrations and Fe(II)%within a
particular environment; given the variability of sputum chemistry
over time (and likely also space) for individual patients (see Fig. S2
and Table S1), averaging and comparing these values per patient
would not have been meaningful.
Fe(II)-responsive genes and multiple iron uptake pathways
are expressed by P. aeruginosa within CF sputum. Given the
abundance of Fe(II) in vitro, we predicted that extracellular Fe(II)
would be bioavailable to P. aeruginosa within the airways. To test
this, we used a quantitative real-time PCR
(qRT-PCR) approach to measure the ex-
pression patterns of two Fe(II)-
responsive genes within expectorated
sputum relative to their expression pat-
terns under controlled conditions. The
P. aeruginosa genes bqsR and bqsS encode
a putative response regulator and sensor
kinase, respectively, of a two-component
system that was previously shown to be
specifically upregulated in response to ex-
tracellular Fe(II) (32). We mined the
NCBI Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov
/geo/) for microarray data generated for
P. aeruginosa grown under conditions
relevant to the CF lung environment.
These data sets revealed no differential
expression of bqsRS in response to multi-
ple environmental stimuli, including low
oxygen, pH, phosphate starvation, oxida-
tive stress, biofilm formation, and various
antibiotic treatments (see Table S2 in the
supplemental material). Thus, bqsRS ex-
pression levels (relative to the constitu-
tively expressed gene oprI) serve as a reli-
able proxy for the bioavailability of Fe(II)
in the lung.
As previously observed, anaerobically
grown laboratory cultures of P. aerugi-
nosa upregulated bqsS (90-fold) in re-
sponse to 50 M Fe(II) relative to no
treatment or treatment with 50 M Fe(III) (Fig. 3A). Likewise,
bqsR was highly expressed (70-fold) in response to Fe(II) rela-
tive to other treatments. We then utilized these gene expression
patterns in controlled cultures to gain insight into the iron oxida-
tion state perceived by P. aeruginosa in sputum. Consistent with
our direct iron analyses, when bqsR and bqsS transcripts from
sputum samples were quantified, expression was detected within
the majority of patients (Fig. 3A). Transcriptional activity varied
between sputum samples; however, 8 of 16 patients harbored rel-
ative bqsS expression patterns comparable to those for Fe(II)-
treated laboratory cultures. bqsR transcripts were also detected in
the majority of sputum samples that we tested, and many had
relative expression levels comparable to those for Fe(II)-treated
planktonic cultures. Unfortunately, technical limitations pre-
vented us frommeasuring gene expression and iron content in the
same sputum sample (seeMaterials andMethods). Despite poten-
tial differences in degradation rates for each transcript (see Fig. S3
in the supplemental material), given the high direct measure-
ments of Fe(II) in sputum, previous microarray data, and our
control experiments showing specific upregulation of bqsRS in
response to Fe(II), we favor the interpretation that the iron pool
within the CF airways is of a mixed oxidation state and that the
infected lung environment frequently includes a ferrous portion
that is sensed by P. aeruginosa.
In a majority (75%) of patients, the prevalences of bqsR and
bqsS gene expression were comparable within patients (see Fig. S4
in the supplementalmaterial); however, therewas not a significant
correlation between bqsRS transcriptional levels and disease sever-
FIG 1 Direct detection of iron abundance and oxidation state within CF sputum. Total iron [Fe(III)
plus Fe(II)] (A), Fe(II) (B), and Fe(II) % (D) all increase as pulmonary function (FEV1%) declines.
There is no significant increase in Fe(III) (C). Each point represents the average of measurements on
multiple sputum samples from a single CF patient.
TABLE 2 Summary of statistical relationships between iron
concentrations and disease severity (FEV1%)
n
Spearman rank
coefficient
Sig.
(two-tailed)
Total iron 24 0.48 0.018
Fe(III) 24 0.21 0.316
Fe(II) 24 0.56 0.004
Fe(II) % 24 0.36 0.083
Bioavailable Ferrous Iron in Cystic Fibrosis Lungs
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ity (bqsR,   0.13; bqsS,   0.01) (see Fig. S5). This is not
surprising because the relative expression of each gene was previ-
ously shown to be upregulated in response to Fe(II) levels greater
than 10 M. In our patient cohort, on average, Fe(II) was fre-
quently detected at levels above 10 M, even in patients in the
early stages of disease. Thus, one would expect expression of these
Fe(II)-sensitive genes across the spectrum of disease severity in
response to the mixed-oxidation state of the iron pool.
A mixed-oxidation state of lung iron is further supported by
our detection of P. aeruginosa gene transcripts encoding diverse
Fe(II)- and Fe(III)-specific uptake proteins (Fig. 3B).We targeted
feoA/B (encoding a ferrous iron transporter), fptA (ferripyochelin
receptor), pvdA (pyoverdine biosynthetic protein), and hasAp
(heme uptake protein) and quantified their relative expression
levels in each sputum sample relative to oprI. Transcripts for each
gene were detected in the majority of sputum samples analyzed
(feoA, 15/16 patients; feoB, 11/16; fptA, 13/16; pvdA, 11/16; hasAp,
14/16), though relative expression levels of each gene varied over 5
orders ofmagnitude between patients. Uptake systems for the two
iron oxidation states were simultaneously expressed within sev-
eral individual patients (see Fig. S4 in the supplemental material),
consistent with a recent study that investigated the expression of
these genes in an independent patient cohort (33). Yet, the expres-
sion of Fe(II) uptake pathways did not correlate with the suppres-
sion of uptake pathways specific for Fe(III), or vice versa. Further-
more, because the regulation of these iron uptake pathways is
complex (34, 35) and some (pvdA, fptA, and hasAp) appear to be
independent from the oxidation state under anoxic conditions
(Fig. 3B), these expression patterns alone are not predictive of the
iron oxidation state in vivo. Rather, the expression ofmultiple iron
uptake systems is supportive of our interpretation that P. aerugi-
nosa utilizes amixed-oxidation pool of ironwithin the CF sputum
environment.
Interfering with bioavailable Fe(II) limits biofilm formation
under anoxic conditions. Given that the
CF sputum environment contains a mix-
ture of Fe(III) and Fe(II), what implica-
tions does this have for treating biofilm
infections? Might abundant Fe(II) levels
in infected environments compromise
the success of Fe(III)-specific chelation
therapies targeting P. aeruginosa? This
was first suggested in a recent study that
tested the efficacy of several iron-binding
compounds in the disruption of P.
aeruginosa biofilm growth under both
oxic and hypoxic conditions (14). While
biofilm formation was prevented under
most conditions tested, the specific oxi-
dation state of iron was unknown. Moti-
vated by these experiments, we utilized a
high-throughput biofilm assay to mea-
sure biofilm formation in the presence of
Fe(III) and Fe(II) with or without
oxidation-state-specific iron chelators.
First, we tested whether ferrozine, a
Fe(II)-specific chelator, could act syner-
gistically with conalbumin, a Fe(III)-
specific chelator, to prevent biofilm de-
FIG 2 Fe(II) percentage of the total iron pool relative to sputum phenazine content. Fe(II) dominates the iron pool at high concentrations of total phenazines
(PYO plus PCA) (A) and phenazine-1-carboxylic acid (PCA) (B) but not pyocyanin (PYO) (C). These data likely reflect the higher reactivity of PCAwith Fe(III)
under anoxic conditions (30).
FIG 3 (A) Fe(II)-relevant gene expression in CF sputum. bqsS is upregulated in planktonic cultures of
P. aeruginosa in response to 50MFe(II) (black) relative to 50MFe(III) (white) or no treatment (light
gray). A similar result is seen with bqsR. Points represent average CT values from three independent
experiments; bars represent the standard deviations. By comparison, expression levels of these Fe(II)-
sensitive genes in CF sputum (dark gray) vary over 5 orders ofmagnitude. Points represent relative gene
expression calculated from CT values from triplicate measurements of an individual sputum sample.
Transcriptional activity is shown relative to the endogenous housekeeping gene oprI. (B) Expression of
diverse iron uptake pathways within CF sputum. feoA and feoB encode proteins that transport Fe(II),
while fptA, pvdA, and hasAp encode proteins that are involved in Fe(III) acquisition. Expression levels
are shown compared to those in laboratory cultures treatedwith Fe(II), Fe(III), and no iron as described
above.
Hunter et al.
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velopment. Consistent with previous studies (10, 14), 100 M
conalbumin prevented biofilm formation by 66% (P  0.001)
under aerobic conditions where all iron (20 M) was Fe(III)
(Fig. 4A). In contrast, 200 M ferrozine [Fe(II) specific] had no
significant effect, nor did the combination of ferrozine and conal-
bumin treatments relative to conalbumin alone. Conversely, un-
der hypoxic conditions designed to mimic airway microenviron-
ments during late-stage infection, conalbumin was ineffective in
preventing biofilm accumulationwhen~10MFe(II) and 10M
Fe(III) were present (Fig. 4B). Here, 200 M ferrozine signifi-
cantly reduced biofilm accumulation by 29% (P  0.012), and
more notably, the combination of 100 M conalbumin and
200 M ferrozine reduced biofilm accumulation by 54% (P 
0.001), suggesting that targeting both oxidation states of iron in
vivo might be more effective than targeting Fe(III) alone in the
prevention of biofilm growth. Under both oxic and anoxic condi-
tions, the addition of 80 M iron (resulting in 100 M total) in
excess of the chelation capacity (conalbumin binds iron in a 2:1
ratio; ferrozine binds in a 3:1 ratio) restored biofilm accumula-
tion, demonstrating that the chelator effect is likely due to iron
sequestration rather than nonspecific interactions.
Combined Fe(III)/Fe(II) chelation promotes biofilm disso-
lution under anoxic conditions. In addition to signaling biofilm
formation, iron is essential formaintenance of established biofilm
communities (12). We therefore performed similar mixed Fe(II)/
Fe(III) chelation experiments targetingmature biofilms to test the
ability of conalbumin and ferrozine to dissolve bacterial biofilms
that have already formed. Under aerobic
conditions (Fig. 4C), the application of
either conalbumin (100M) or ferrozine
(200 M) in molar excess of iron in the
growth medium showed minimal effect
on biofilm dissolution. We hypothesized
that this is due to the presence of both
Fe(III) and Fe(II) in the hypoxic interior
of aerobically grown biofilms. Consistent
with this prediction, the combined appli-
cation of both Fe(III) and Fe(II) chelators
revealed a synergistic dissolution effect,
resulting in a 33% reduction (P 0.01) of
biomass in the presence of oxygen. The
addition of excess iron restored the un-
treated phenotype, corroborating an
iron-specific mechanism of chelator-
induced dispersal. Similarly, 100 M
conalbumin did not significantly reduce
established biofilm growth under anoxic
conditions (Fig. 4D). However, signifi-
cant biofilmdissolution (20%;P 0.001)
was observed in the presence of 200 M
ferrozine, indicating that P. aeruginosa
biofilms can reduce Fe(III) present in the
growthmedium.More notably, when ap-
plied together with conalbumin, ferro-
zine promoted further dissolution of es-
tablished biofilms at levels comparable to
those under oxic conditions (28%; P 
0.001), supporting the case for targeting
both Fe(III) and Fe(II) to disrupt
P. aeruginosa biofilm growth in the CF
airways. In contrast to previous experiments performed under
oxic conditions (15), dual exposure to iron chelators and tobra-
mycin did not exhibit a synergistic effect under anoxic conditions
(see Fig. S6 in the supplemental material).
DISCUSSION
The dependence of bacteria on iron acquisition for biofilm forma-
tion has led to its identification as a novel therapeutic to eliminate
P. aeruginosa infections within the host, particularly for CF pa-
tients. However, as recently pointed out (14), there is a gap in our
understanding of the in vivo chemical environments under which
these treatmentsmight be administered, whichmight significantly
impact their efficacy. Therefore, the goal of this study was to gain
a better understanding of iron chemistry within the lungs of CF
patients anddetermine how the in vivo environmentmight impact
the success of iron-specific therapies.Using a unique sputum sam-
pling and processing approach, we determined that Fe(II) com-
prises a significant component of the airway iron pool. We then
used quantitative PCR analysis to confirm that elevated Fe(II)
levels were freely available for the infecting bacterial population.
Finally, we found that interfering with a mixed-oxidation state
iron pool can limit biofilm formation and promote biofilm disso-
lution.
On average, each patient had 42 M total iron (range, 3.7 to
118 M) present in his or her sputum, which was highly depen-
dent on the stage of disease (Table 1). These values are consistent
with a range of studies reporting elevated iron levels in CF sputum
FIG 4 (A and B) Biofilm growth prevention under aerobic conditions [~98% Fe(III)] (A) and anaer-
obic conditions [~10 M Fe(II) and 10 M Fe(III)] (B) by conalbumin [a Fe(III) chelator] and ferro-
zine [a Fe(II) chelator]. (C and D) Biofilm dissolution under aerobic (C) and anaerobic (D) conditions
by conalbumin and ferrozine. In all cases, chelator effects aremitigated by the addition of Fe in excess of
the chelation capacity [80 M Fe(III) under oxic conditions; Fe(II) under anoxia]. Asterisks represent
significance versus untreated controls. Error bars represent standard errors of the means (n 12).
Bioavailable Ferrous Iron in Cystic Fibrosis Lungs
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and bronchoalveolar lavage. For example, Reid et al. (24) and
Stites et al. (25) both determined that free iron and ferritin nega-
tively correlate with pulmonary function in clinically stable pa-
tients. Similarly, Gifford et al. (36) reported elevated sputum iron
levels in CF patients and yet found no association between Fe
concentrations and lung function in a mixed cohort of stable and
acutely ill subjects. Although we found a correlation between total
iron and FEV1%, this derives from Fe(II), not Fe(III).
Despite the wealth of data on total iron abundance in the CF
airways, to our knowledge, direct measurements of the iron oxi-
dation state have not been made previously. It has been suggested
that the abnormal acidification of the CF airways (37) and the
development of anoxic microenvironments in sputum (5) favor
the maintenance of a bioavailable Fe(II) pool; however, the rapid
oxidation of Fe(II) upon exposure to ambient oxygen has made
this hypothesis difficult to test. Our novel sputum sampling and
processing approachwas able to circumvent this problem, and it is
clear that the percentage of the total iron pool that is Fe(II) is
substantial, particularly in severely ill patients (56%  15%).
While our data support the aforementioned low-pH/anoxic hy-
pothesis for iron reduction, it also seems likely that the accumu-
lation of redox-active phenazines over time contributes to a highly
reducing airway environment that can foster Fe(III) reduction to
Fe(II) (Fig. 2). Based on our laboratory observations that PCA-
mediated iron reduction facilitates biofilm formation (31) and a
correlation between concentrations of these metabolites and pul-
monary decline (22), we suggest that PCA-mediated iron reduc-
tion facilitates disease progression in CF patients.
We recognized a need to distinguish between detectable Fe(II)
levels (by ferrozine) and thosewhich are bioavailable forP. aerugi-
nosa in vivo. For example, the total soluble iron measurements
determined by our analytical approach likely include a portion
that is bound to complexing ions or ligands that keep it in solu-
tion, though it might not be bioavailable. Moreover, ferrozine
does not react with heme-associated iron (38), which may repre-
sent an important iron source within the lung (4, 9). However,
because we could detect a high level of Fe(II)-specific bqsRS ex-
pression (relative to oprI) in a majority of sputum samples (com-
pared to tightly controlled laboratory cultures), we can conclude
that some portion of the Fe(II) pool is sensed by P. aeruginosa in
vivo. Consistent with previous in vitro studies demonstrating that
P. aeruginosa grown in the presence of a sputum-derivedmedium
expresses diverse iron-acquisition-related genes (4), we found
genes involved in pyoverdine, pyochelin, and heme uptake to be
expressed in sputum, similar to another recent study (33). In ad-
dition, direct measurements have also confirmed the presence of
the siderophore pyoverdine in a high percentage of CF patients,
but not all, indicating that P. aeruginosa uses multiple mecha-
nisms for iron acquisition within the host (52). Intriguingly, our
data indicate that multiple iron uptake pathways are expressed
simultaneously in several patients and that several (e.g., pvdA,
fptA, and hasAp) do not appear to be iron responsive under anoxic
conditions (Fig. 3B). This apparent loss of Fur regulationmay also
reflect mutations that accrue as infections progress, as has been
documented elsewhere (39). A more thorough understanding of
iron-relevant gene regulation in vivo will be necessary to deter-
mine how expression patterns of iron uptake machinery may in-
form us about the chemical environment of the airways.
Because bioavailable iron serves as a signal for biofilm forma-
tion (12) and as an integral cation for biofilm stability (40), it is
thought to be required for both the establishment of P. aeruginosa
biofilms and their chronicity in CF patients (14, 24). It has also
been established that an optimal concentration of iron is required
for the formation of P. aeruginosa biofilms (10, 41). In a biofilm
mode of growth, it is generally accepted that bacterial cells are
inherently more resistant to antibiotics and components of the
host immune system, and only once they revert to their planktonic
state are they readily cleared (42). In our studies, the mixed-
oxidation approach (conalbumin/ferrozine) to iron chelation ap-
pears to be promising in preventing biofilm formation, and we
predict that under oxic conditions, it will further sensitize biofilm
cells to conventional antimicrobial treatments, as has previously
been shown (13, 15). However, mixed Fe(III)/Fe(II) chelation
may be most significant under anoxic conditions (thought to be
prevalent throughout the CF airways [5]), by preventing or dis-
rupting biofilms. While cells reverting to a planktonic lifestyle
would likely remain tolerant to conventional antibiotics due to
slow anaerobic growth andphysiological changes (43), theywould
no longer be as protected from the host immune response, and
possibly more readily cleared from the host environment. Testing
this hypothesis in infection models is a logical next step. A chal-
lenge will be to ensure that these infection models accurately
mimic the environment of the human host for chronic infections.
Collectively, these studies underscore the importance of a dia-
lectic between laboratory and environmental studies of pathogens
such as P. aeruginosa. To complement mechanistic studies at the
bench, characterization of the microbial community in vivomust
also include an analysis of the chemical conditions under which it
lives. Such combined efforts will provide insight into how infected
environments coevolve with the composition and activities of the
constituent microbiome at different stages in disease progression.
As suggested here, this integrated approach has the potential to
inform effective design and application of novel therapeutic strat-
egies for P. aeruginosa biofilm control.
MATERIALS AND METHODS
Study design and sample collection. Twenty-five participants (aged 7 to
20 years) and eight participants (aged 16 to 38 years) were recruited from
Children’s Hospital Los Angeles (CHLA) and the Academic Hospital UZ
Brussel, respectively. Inclusion criteria were a positive diagnosis of CF,
ability to expectorate sputum, and informed consent. Sputum was flash
frozen in liquid nitrogen shortly after expectoration to minimize oxida-
tion and/or mRNA degradation and stored at 80°C until processing.
Disease severity was determined by FEV1% scores, and patients were clus-
tered using published guidelines (44, 45). This study was approved by the
ethical commissions of the California Institute of Technology, Children’s
Hospital Los Angeles, and the Academic Hospital UZ Brussel.
Sputum processing. Frozen samples were thawed in an anaerobic
chamber. Sputumwas disrupted using a 16-gauge needle andwas homog-
enized by vortexing in an equal volume of anoxic 50 mM HEPES buffer.
Sputum was centrifuged at 8,000 g for 10 min, and supernatants were
filtered through 0.22-m-pore-size columns for 20 min at 10,000  g.
Filtrates were analyzed for iron content.When sufficient sputummaterial
was obtained, 200 l of filtrate was stored at80°C for inductively cou-
pled plasma mass spectrometry (ICP-MS) analysis.
Iron quantification. Iron levels were quantified using the ferrozine
assay (46). Briefly, 50 l of sputum filtrate was carefully added (to avoid
introducing bubbles) to 50l of 1MHCl to quantify Fe(II). For total iron,
50l was treated with 50l of 10% hydroxylamine hydrochloride in 1M
HCl to reduce Fe(III) to Fe(II). Samples were added to 100l of ferrozine
(0.1% [wt/vol] in 50%ammoniumacetate) and incubated for 15min, and
absorbance was measured at 562 nm. Ferrous ammonium sulfate was
Hunter et al.
6 ® mbio.asm.org July/August 2013 Volume 4 Issue 4 e00557-13
 
m
bio.asm
.org
 o
n
 M
ay 24, 2017 - Published by 
m
bio.asm
.org
D
ow
nloaded from
 
used as the iron standard. Samples were also analyzed by inductively cou-
pled plasma mass spectrometry (ICP-MS). Briefly, 50 l of filtrate was
digested in 100 l 8 N nitric acid and brought to a total of 1.5 ml in 5%
nitric acid-indium standard. Samples were analyzed on an Agilent 7500cx
analyzer equipped with a reaction cell, using He (2 ml/min) and H2
(2.5 ml/min) as reaction gases. Fe concentrations were calculated using
56Fe and 57Fe signal intensities.
SputummRNA extraction and quantitative real-time PCR. Sputum
samples were collected, frozen, and homogenized as described above. Un-
der anoxic conditions, homogenate was added to 1 vol of 0.1-mmzirconia
beads and 3 volumes of Trizol LS, and mRNA was extracted as described
by Lim et al. (47). Purity and degradation were assessed using NanoDrop
spectrophotometry, agarose gel electrophoresis, and an Agilent 2100 Bio-
analyzer. cDNA was reverse transcribed from 1 g of total RNA with the
first-strand cDNA synthesis kit (Amersham Biosciences) or iScript (Bio-
Rad) according to themanufacturer’s protocols. cDNAwas then used as a
template for quantitative PCR (RealTime 7500 PCR machine; Applied
Biosystems) using SYBR green with the ROX detection system (Bio-Rad).
Triplicatemeasurements weremade on each sputum sample. As controls,
anaerobically grownP. aeruginosaPA14 treatedwith 50MFe(II), 50M
Fe(III), or water (no iron)was assayed as previously described (32). For all
primer sets (see Table S3 in the supplemental material), the following
cycling parameterswere used: 94°C for 3min followed by 40 cycles of 94°C
for 60 s, 55°C for 45 s, and 72°C for 60 s, followed by 72°C for 7 min. oprI
and clpX were used to normalize levels of gene expression (48, 49) (see
Fig. S3). Primer efficiencies were determined using iQ5 optical system
software (Bio-Rad), and standard curves were constructed based on four
different known quantities of genomic DNA of P. aeruginosa PAO1
(100 ng, 50 ng, 10 ng, and 5 ng) (see Table S3). The threshold cycle (CT)
values of each gene were used to calculate relative gene expression using
the 2CTmethod (50). The mRNA extraction protocol precluded a con-
current Fe(II) measurement because the coloration of the Trizol reagent
interferes with the ferrozine assay.
HPLC quantification of phenazines. Phenazine extraction and quan-
tification were performed anaerobically as previously described (22).
Ninety-seven out of 115 samples contained sufficient sputummaterial for
phenazine analysis (3).
MBECassay for biofilmprevention anddissolution.Weused a high-
throughput biofilm assay (MBEC physiology and genetics assay) consist-
ing of a 96-well plate and 96-peg lid. Inoculum was prepared by diluting
(30-fold) a 107-cell/ml suspension of P. aeruginosa PA14 in Trypticase soy
broth (TSB). One hundred fiftymicroliters was dispensed into each of the
60 inner wells, while 200 l of sterile TSB was placed in each perimeter
well. For dissolution experiments, plates were incubated at 37°C for 24 h,
and lids were transferred to a fresh 96-well TSB plate for 24 h at 37°C or to
an anaerobic chamber for 24 h at 37°C in anaerobic TSB containing
50 mM KNO3. Biofilms were exposed to 100 M conalbumin and/or
200 M ferrozine for 24 h (concentrations were selected such that they
were in molar excess of medium iron concentrations). The dual chelator
treatment was also complemented with 8 g/ml tobramycin or 80 M
ferrous ammonium sulfate where indicated. After treatment, lids were
rinsed once in 50 mM HEPES, air dried for 10 min, and quantified by
crystal violet staining (51). For biofilm growth prevention assays, both
aerobic and anaerobic inocula were amended with 100 M conalbumin
and/or 200 M ferrozine. For aerobic experiments, biofilms developed
for 24 h. For anaerobic growth, the medium was replaced every 24 h by
transferring the lid to a sterile plate containing TSB with or without treat-
ments, and biofilms were developed for 168 h.
Statistical analysis. Spearman rank analysis () was performed on
iron and phenazine concentrations versus lung function (Fig. 1 and
2).Two-tailed Student t tests were used for pairwise comparisons between
chelator treatments and controls (Fig. 4). In all cases, P  0.05 was con-
sidered statistically significant.
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